Global Impact of Covid-19 coronavirus on “non-Covid” clinical trials

Zara Sproul

In recent weeks and months, the life sciences sector has been the focal point of efforts to respond to the Covid-19 threat.  While these efforts have – justifiably – occupied many of the headlines, this blog post looks at the impact of the pandemic on “non-Covid” focused clinical trials and steps taken to limit disruption Read More

Advocate General of the CJEU considers French ban on hemp-derived cannabidiol (CBD) contrary to EU law

Eveline Van Keymeulen

Yesterday, Advocate General Tanchev presented his long-awaited opinion before the Court of Justice of the European Union (CJEU) in Case C-663/18 (Kanavape) stating that the general ban on natural cannabidiol (CBD) in France is contrary to EU law. It is the first time that the highest European Court, including the Advocate General, has been requested Read More

Data as a critical asset in the health sector

Laurie-Anne Ancenys

Laurie-Anne Ancenys, Counsel, Head of the Paris Tech & Data practice, and Juliette Olliveaud, Associate, look at how the ever-growing volume of data in our digital world presents both challenges and opportunities for patients and healthcare providers. The collection of vast sets of data and their subsequent valuation and monetisation has become a driving force Read More

Covid-19 coronavirus: EMA Fast Track Procedures for Medicines and Vaccines

Rafi Allos

The European Medicines Agency (EMA) announced on 4 May that the EMA will accelerate regulatory procedures for supporting R&D of, and evaluating marketing authorisation applications (MAAs) for, medicines and vaccines for Covid-19 coronavirus.  Further details regarding these measures are in an inventory published with the announcement.  These measures are available both for new medicines and Read More

EU data protection guidance on Covid-19 apps

Nieke Vanavermaete

On 16 April 2020, the European Commission issued a Guidance on Apps supporting the fight against COVID 19 pandemic in relation to data protection (the Guidance). The aim is to set out requirements which apps should meet to ensure compliance with EU privacy legislation, in particular the GDPR and the ePrivacy Directive. The Guidance is Read More